Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001338

Drug Information
SynonymsNCGC00095118-01; Merck Frosst brand of rofecoxib; KBioGR_002345; MK 996; Merck brand of rofecoxib; MK 966; MolPort-006-817-786; C07590; MK 0966; Spectrum4_000631; BSPBio_002705; KBio1_001709; Vioxx (trademark); Spectrum_000119; SPBio_000492; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; HMS2093E04; AKOS000280931; Merck Sharp & Dhome brand of rofecoxib; 186912-82-3; Cahill May Roberts brand of rofecoxib; cMAP_000024; KBioGR_001242; SpecPlus_000669; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; STK635144; SMR000466331; DivK1c_006765; Spectrum2_000446; KBio2_005695; CPD000466331; Bio-0094; HMS2089H20; MLS001165770; AC-13144; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; KBio2_000559; MolPort-000-883-878; CID5090; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; CHEMBL122; KBioSS_000559; CCRIS 8967; Vioxx; KBio2_007481; CHEBI:8887; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; KS-1107; KBio2_002345; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; DB00533; LS-70511; KBio2_004913; NSC720256; KBio2_003127; 2(5H)-Furanone, 4-[4-(methyl-sulfonyl)phenyl]-3-phenyl-; HMS1922H11; KBio3_002205; Jsp003237; HMS2051G16; C17H14O4S; 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; Vioxx (TN); 2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-; NCGC00095118-04; Rofecoxib (JAN/USAN/INN); FT-0081390; ZINC00007455; refecoxib; KBio3_002825; MK0966; NCI60_041175; Vioxx Dolor; MLS001195623; D00568; Ceoxx; KBioSS_002348; MSD brand of rofecoxib; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one; UNII-0QTW8Z7MCR; L000912; MLS000759440; 162011-90-7; Spectrum5_001598; HSDB 7262; SPECTRUM1504235; MK-0966; Spectrum3_001153; SAM001246617; NCGC00095118-02; MK-966; MLS001424113; NCGC00095118-03; I01-1042; BIDD:GT0399; rofecoxib; BRD-K21733600-001-02-6; AC1L1JL6; C116926; MK 0996    
Trade NameVioxx; Ceoxx; Ceeoxx    
CompanyMerck & Co    
IndicationOsteoarthritisWithdrawn    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Inflammatory Agents    
CAS NumberCAS 162011-90-7
PubChem Compound IDCID 5090.    
PubChem Substance IDSID 9792.    
SuperDrug ATC IDM01AH02;    
SuperDrug CAS ID162011907;    
Ref 1New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference
Ref 3Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference
Ref 4Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. To Reference
Ref 5The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 2003 Sep;125(3):716-29. To Reference
Ref 6Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (Oxford). 2002 Apr;41 Supp 1:16-22; discussion 35-42. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543